The polymorphism of multi-drug resistance 1 gene (MDR1) does not influence the pharmacokinetics of Dexamethasone loaded into autologous erythrocytes of patients with inflammatory bowel disease

European Review for Medical and Pharmacological Sciences

Volumn 10, Issue 1, 2006, Pages 27-31

  Annese, V ^a   Latiano, A ^a   Rossi, L ^b   Bossa, F ^a   Damonte, G ^c   Dallapiccola, B ^a,d,e   Serafini, S ^b   Pierige F ^b   Andriulli, A ^a   Magnani, M ^b  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b UNIVERSITY OF URBINO   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e Mendel Institute   (Italy)

Author keywords

Crohn's disease; Infliximab; SonoVue; Ultrasonography

Indexed keywords

CORTICOSTEROID; CYSTEINE; DEXAMETHASONE SODIUM PHOSPHATE; GENOMIC DNA; MULTIDRUG RESISTANCE PROTEIN 1; THREONINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CROHN DISEASE; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; DNA POLYMORPHISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG INFUSION; ELECTROSPRAY MASS SPECTROMETRY; ENTERITIS; ERYTHROCYTE; FEMALE; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MALE; PATIENT SELECTION; SIDE EFFECT; ULCERATIVE COLITIS; WILD TYPE;

ADULT; COLITIS, ULCERATIVE; CROHN DISEASE; DEXAMETHASONE; DRUG CARRIERS; ERYTHROCYTES; FEMALE; GENES, MDR; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PRODRUGS;

EID: 33644544727     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Banerjee S, Peppercorn MA. Inflammatory bowel disease. Medical therapy of specific clinical presentations. Gastroenterol Clin N Am 2002; 31: 185-202.
2. Keenan GF. Management of complication of glucocorticoid therapy. Clin Chest Med 1997; 18: 507-520.
3. Faubion WA, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001; 121: 255-260.
4. Munkholm P, Langholz E, Davidsen M, Binder V Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994; 35: 360-362.
5. Dascenzo M, Antonelli A, Charantinini L, Mancini U, Magnani M. Red blood cells as a glucocorticoids delivery system. In: Sprandel U, Way JL (eds): Erythrocytes as drug carriers in medicine. Plenum Press, New York, pp. 81-8, 1997.
6. Magnani M, Rossi L, D'Ascenzo M, Panzani I, Bigi L, Zanella A. Erythrocyte engineering for drug delivery and targeting. Biotechnol Appl Biochem 1998; 28: 1-6.
7. Annese V, Latiano A, Rossi L, Lombardi G, Dallapic-Cola B, Serafini S, et al. Erythrocytes-mediated delivery of dexamethasone in steroid-dependent IBD patients-a pilot uncontrolled study. Am J Gastroenterol 2005; 100: 1370-1375.
8. Thiebaut F, Tsuruo T, Hamada H, et al. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987; 84: 7735-7738.
9. Watkins PB. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv Drug Deliv Rev 1997; 27: 161-170.
10. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999; 39: 361-398.
11. Fromm MF. The impact of MDR1 polymorphism on P-glycoprotein expression and function in humans. Adv Drug Deliv Rev 2002; 54: 1295-1310.
12. Ishikawa T, Onishi Y, Hirano H, Oosumi K, Nagakura M, Taruis S. Pharmacogenomics of drug transporters: a new approach to functional analysis of the genetic polymorphism of ABCB1 (P-glycoprotein/MDR1). Biol Pharm Bull 2004; 27: 939-948.
13. Fromm MF. Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci 2004;25: 423-429.
14. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV Schwartz UI, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001; 70: 189-199.
15. Hoffmeyer S, Burk O, Von Richter O, Arnold HP, Brockmoller J, Johne A, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97: 3473-3478.
16. Hitzl M, Drescher S, Van Er Kuip H, Schaffeler E, Fischer J, Schwab M, et al. The C3435T mutation in the human MDR1 gene is associated with altered efflux of the glycoprotein substrate rhodamine123 from CD56+ natural killer cells. Pharmacogenetics 2001; 11: 293-298.
17. Morita N, Yasumori T, Nakayama K. Human MDR1 polymorphism: G2677T/A and C3435T have no effect on MDR1 transport activities. Biochem Pharmacol 2003; 65: 1843-1852.
18. Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, et al. Frequency of single nucleotide polymorphism in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001; 69: 169-174.
19. Podolsky DK. Inflammatory bowel disease. New Engl J Med 2002; 347: 417-429.
20. Sutherland LR, Martin F, Greer S, et al. 5-aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 1987; 92: 1894-1898.
21. Best WR, Beckiel JM, Singleton JW, Kern F. Development of a Crohn's disease activity index. Gastroenterology 1976; 70: 439-444.
22. Palmieri O, Latiano A, Valvano R, D'Inca R, Vecchi M, Sturniolo GC, et al. Multidrug resistance 1 gene polymorphisms are not associated with inflammatory bowel disease and response to therapy in Italian patients. Aliment Pharmacol Ther 2005; 22: 1129-1138.